OmniAb Plans to Secure $30 Million Through Private Stock Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 25 2025
0mins
Source: SeekingAlpha
Private Placement Agreement: OmniAb has finalized a private placement agreement to raise approximately $30 million by issuing 21,254,106 shares at $1.40 each.
Use of Proceeds: The net proceeds from this financing will be utilized for general corporate purposes, with the transaction expected to close around August 26, 2025.
Investor Participation: The financing round includes participation from both new and existing top-tier investors, as well as company officers and directors.
Stock Performance: Following the announcement, OABI stock experienced a decline of 10.81% in premarket trading on Monday.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like OABI with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on OABI
Wall Street analysts forecast OABI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OABI is 6.80 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.850
Low
3.00
Averages
6.80
High
11.00
Current: 1.850
Low
3.00
Averages
6.80
High
11.00
About OABI
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OmniAb Launches First Transgenic Chicken Platform, Expanding Therapeutic Opportunities
- Platform Innovation: OmniAb launched the OmniUltra™ platform at the Antibody Engineering & Therapeutics Conference in San Diego, marking the industry's first transgenic chicken platform capable of expressing ultralong CDRH3 domains, significantly broadening therapeutic applications.
- Technical Advantages: The platform generates antibodies and picobodies™ with high specificity and structural stability, accelerating the drug discovery process, particularly showcasing immense potential in bispecific and multispecific drug development.
- Market Prospects: The launch of the OmniUltra platform is expected to attract strong interest from industry partners, further solidifying OmniAb's leadership in next-generation drug discovery and facilitating entry into new markets.
- Industry Engagement: OmniAb is conducting two presentations at the conference, highlighting the broad applicability of its technology and emphasizing the platform's significance in the discovery of novel mini-proteins and structured peptides, enhancing interaction with potential customers.
Continue Reading
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4
- Clinical Progress: GT Biopharma's GTB-3650 has advanced to Cohort 4 in its clinical trial at a dose of 10 µg/kg/day, demonstrating good tolerability and potential efficacy, which is expected to provide new treatment options for patients with refractory blood cancers.
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, with monoclonal antibodies and cell therapies leading this growth, positioning GT Biopharma within this rapidly expanding sector.
- Technological Advantage: GTB-3650 employs the company's proprietary TriKE platform technology to stimulate patients' natural killer cells to target cancer cells, showing promise in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Future Plans: The company plans to provide the next trial update in Q1 2026 and expects to submit a regulatory application for GTB-5550 by late December 2025 or January 2026, further expanding its therapeutic pipeline.
Continue Reading